SCHEMBL59853

SCHEMBL59853

CCC=CC/[C]=C/C(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28454816 0.77
SCHEMBL6119691 0.69
SCHEMBL6119693 0.69
SCHEMBL17219829 0.69
SCHEMBL11052069 0.65
SCHEMBL1401893 0.65 FFAR1 (0.31)
SCHEMBL20660 0.63
SCHEMBL120668 0.63
SCHEMBL55475 0.63
SCHEMBL10392673 0.62

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1270 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112689634-B SMAD3 inhibitors 莫扎制药有限公司 2024-07-16 CN disclosed
CN-118355029-A Methods of treating diffuse large B-cell lymphomas using anti-CD 79B immunoconjugates 基因泰克公司 2024-07-16 CN disclosed
US-20240226342-A1 REACTIVE OXYGEN SPECIES IMAGING AGENTS WASHINGTON UNIVERSITY (US) 2024-07-11 US disclosed
US-12016842-B2 Methods of using anti-CD79b immunoconjugates GENENTECH, INC. (US) 2024-06-25 US disclosed
CN-118201946-A Lipidated polymyxin analogues 奥克兰联合服务有限公司 2024-06-14 CN disclosed
WO-2024121632-A1 USE OF ANTI-CD117 ANTIBODY DRUG CONJUGATE (ADC) CRISPR THERAPEUTICS AG (CH) 2024-06-13 WO disclosed
EP-4380978-A1 METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES TO TREAT DIFFUSE LARGE B-CELL LYMPHOMA Genentech, Inc. (US) 2024-06-12 EP disclosed
US-12006370-B2 Use of anti-CD5 antibody drug conjugate (ADC) in allogeneic cell therapy HEIDELBERG PHARMA RESEARCH GMBH (DE) 2024-06-11 US disclosed
WO-2024110905-A1 ANTI-CEA ANTIBODY DRUG CONJUGATES AND METHODS OF USE BEIGENE, LTD. (KY) 2024-05-30 WO disclosed
US-20240179825-A1 SYSTEMS AND METHODS FOR NONEQUILIBRIUM PLASMAS WASHINGTON UNIVERSITY 2024-05-30 US disclosed
WO-2004009610-A2 USE OF NUCLEOSIDE COMPOUNDS FOR NONSENSE SUPPRESSION AND THE TREATMENT OF GENETIC DISEASES PTC THERAPEUTICS, INC. (US) 2004-01-29 WO disclosed
WO-2004009609-A2 NUCLEOSIDE COMPOUNDS AND THEIR USE FOR TREATING CANCER AND DISEASES ASSOCIATED WITH SOMATIC MUTATIONS PTC THERAPEUTICS, INC. (US) 2004-01-29 WO disclosed
WO-2004009533-A1 ACETYLAMINO BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE PTC THERAPEUTICS, INC. (US) 2004-01-29 WO disclosed
WO-2004002983-A2 THERAPEUTIC PIPERAZINE DERIVATIVES USEFUL FOR TREATING PAIN EURO-CELTIQUE, S.A. (LU) 2004-01-08 WO disclosed
US-20040006091-A1 Therapeutic agents useful for treating or preventing pain PURDUE PHARMA L.P. 2004-01-08 US disclosed
WO-2003105774-A2 COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER, COMPOSITIONS THEREOF AND METHODS THEREWITH SIGNAL PHARMACEUTICALS, INC. (US) 2003-12-24 WO disclosed
WO-2003102151-A2 MODULATING CELL DIFFERENTIATION AND TREATING MYELOPROLIFERTIVE DISORDERS WITH JNK/MKK INHIBITORS CELGENE CORPORATION (US) 2003-12-11 WO disclosed
WO-2003093236-A1 1-(PYRID-2-YL)-PIPERAZINE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR INHIBITOR EURO-CELTIQUE, S.A. (LU) 2003-11-13 WO disclosed
WO-2003074520-A1 THIADIAZOLYLPIPERAZINE DERIVATIVES USEFUL FOR TREATING OR PREVENTING PAIN EURO-CELTIQUE, S.A. (LU) 2003-09-12 WO disclosed
WO-2003066595-A2 2 - PIPERAZINE - PYRIDINES USEFUL FOR TREATING PAIN EURO-CELTIQUE S.A. (LU) 2003-08-14 WO disclosed